Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2010 - 2026)

Jazz Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 320.69% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $37.3 million (up 152.52% YoY), while the FY2025 annual figure was $28.0 million, up 171.34% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $12.2 million, up from -$22.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $148.1 million in Q4 2022, with the low at -$97.0 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $7.2 million (2023), against an average of $8.5 million.
• The sharpest annual moves came in 2024 and 2026: Change in Accured Expenses plunged 507.87% in 2024, then surged 320.69% in 2026.
• Jazz Pharmaceuticals' Change in Accured Expenses stood at $148.1 million in 2022, then sank by 64.21% to $53.0 million in 2023, then slumped by 280.51% to -$95.7 million in 2024, then soared by 76.06% to -$22.9 million in 2025, then surged by 153.26% to $12.2 million in 2026.
• Business Quant data shows JAZZ's Change in Accured Expenses at $12.2 million in Q1 2026, -$22.9 million in Q4 2025, and $126.3 million in Q3 2025.